Send to printer »

GEN News Highlights : Jul 27, 2009

RXi Gains Rights to Advirna’s RNAi Delivery Platform

Technology will help RXi develop therapeutics that do not use delivery vehicles like liposomes.

RXi Pharmaceuticals exercised its option to acquire an exclusive, worldwide license to Advirna’s RNAi delivery technology. The technologies licensed from Advirna encompass four approaches, focused primarily on self-delivery of RNAi therapeutics.

Advirna’s technology has been integrated into RXi’s rxRNA™ platform to generate so-called self-delivering rxRNAs (sd-rxRNAs), which the company maintains require no separate delivery vehicle such as liposomes, complexes, or nanoparticles. Additional advantages of the new sd-rxRNAs are reported to include their spontaneous cellular uptake, patient-friendly (subcutaneous) administration, tissue-targeted biodistribution/reduced renal clearance, and reduced side-effects. 

“The ability to create self-delivering RNAi therapeutics promises to provide significant competitive advantages in efficacy, toxicity, ease of administration, and manufacturing costs,” states RXi president and CEO, Tod Woolf, Ph.D.